JW (Cayman) Therapeutics Co. Ltd (HKG:2126)
Hong Kong · Delayed Price · Currency is HKD 1.960
+0.100 (5.38%)
At close: Mar 27, 2026
HKG:2126 Revenue
In the year 2025, JW (Cayman) Therapeutics Co. had annual revenue of 283.65M CNY with 79.28% growth. JW (Cayman) Therapeutics Co. had revenue of 106.35M in the half year ending June 30, 2025, with 21.21% growth.
Revenue
283.65M CNY
Revenue Growth
+79.28%
P/S Ratio
2.52
Revenue / Employee
971.41K CNY
Employees
292
Market Cap
795.05M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 283.65M | 125.44M | 79.28% |
| Dec 31, 2024 | 158.22M | -15.64M | -8.99% |
| Dec 31, 2023 | 173.86M | 28.15M | 19.32% |
| Dec 31, 2022 | 145.70M | 114.91M | 373.10% |
| Dec 31, 2021 | 30.80M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Uni-Bio Science Group | 589.59M |
| 3D Medicines | 491.34M |
| Wuhan YZY Biopharma | 163.65M |
| CANbridge Pharmaceuticals | 68.55M |
| Beijing Biostar Pharmaceuticals | 58.66M |
| Brii Biosciences | 39.56M |
| Kintor Pharmaceutical | 12.04M |
| Transcenta Holding | 10.31M |